ACR 2025 Rheumatology Round Up

Jack Cush, MD

Nov 03, 2025 12:23 pm

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.

ADD THE FIRST COMMENT

If you are a health practitioner, you may Login/Register to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

Topics

ACR 2025 Rheumatology Round Up Save

ADD THE FIRST COMMENT

Most Popular Stories

Virtual Posters

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

Topics

Do you get our email newsletter?